@article{1020d3bdd20c481cb09ea2e0b5dabbdd,
title = "Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology: Clinical practice guidelines in oncology",
abstract = "This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.",
keywords = "Biomarkers, Carcinoma, Non-Small-Cell Lung/diagnosis, Clinical Trials as Topic, Combined Modality Therapy, Disease Management, Humans, Immunotherapy, Lung Neoplasms/diagnosis, Molecular Targeted Therapy, Neoplasm Metastasis, Prognosis, Recurrence, Treatment Outcome",
author = "Ettinger, {David S.} and Wood, {Douglas E.} and Aisner, {Dara L.} and Wallace Akerley and Jessica Bauman and Chirieac, {Lucian R.} and D'Amico, {Thomas A.} and Decamp, {Malcolm M.} and Dilling, {Thomas J.} and Michael Dobelbower and Doebele, {Robert C.} and Ramaswamy Govindan and Gubens, {Matthew A.} and Mark Hennon and Leora Horn and Ritsuko Komaki and Lackner, {Rudy P.} and Michael Lanuti and Leal, {Ticiana A.} and Leisch, {Leah J.} and Rogerio Lilenbaum and Jules Lin and Loo, {Billy W.} and Renato Martins and Otterson, {Gregory A.} and Karen Reckamp and Riely, {Gregory J.} and Schild, {Steven E.} and Shapiro, {Theresa A.} and James Stevenson and Swanson, {Scott J.} and Kurt Tauer and Yang, {Stephen C.} and Kristina Gregory and Miranda Hughes",
note = "Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network.",
year = "2017",
month = apr,
day = "1",
doi = "10.6004/jnccn.2017.0050",
language = "English",
volume = "15",
pages = "504--535",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",
}
